Balance Sheet Components

9 Months Ended

Sep. 30, 2021

Balance Sheet Related Disclosures [Abstract]

Balance Sheet Components

Balance Sheet Components

Cash, Cash Equivalents and Restricted Cash

A reconciliation of cash, cash equivalents and restricted cash reported within the condensed consolidated balance sheets to the amount reported within the condensed consolidated statements of cash flows is as follows (in thousands):

	September 30, 2021		December 31, 2020
Cash and cash equivalents	$	145,826	$	147,017
Restricted cash	1,499		1,499
Total cash, cash equivalents and restricted cash	$	147,325	$	148,516

Property and Equipment

Property and equipment consisted of the following (in thousands):

	September 30, 2021		December 31, 2020
Leasehold improvements	$	25,880	$	25,880
Laboratory equipment and office furniture	23,057		23,638
Computer equipment	1,190		1,271
Construction in process	68		48
Total property and equipment, gross	50,195		50,837
Less: accumulated depreciation and amortization	(38,743)		(36,311)
Total property and equipment, net	$	11,452	$	14,526

Depreciation expense was $1.5 million and $4.6 million for the three and nine months ended September 30, 2021, respectively, compared to $1.6 million and $5.0 million for the same periods in 2020.

Accrued Liabilities

Accrued liabilities consisted of the following (in thousands):

	September 30, 2021		December 31, 2020
Clinical trials and research and development costs	$	12,984	$	9,316
Manufacturing costs	9,993		8,297
Personnel-related costs	9,309		8,921
Accrued expenses	2,434		3,411
Total accrued liabilities	$	34,720	$	29,945